ClinicalTrials.gg
RecruitingNCT04613349NEFAPAUpdated Jan 5, 2026

FArial NErf MRI in the Preoperative Assessment of PArotide Tumors

An observational study in Parotid Tumor, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
88
Ages
18 Years and older
Sex
All
01

Study summary

  1. st visit: Inclusion, 3Tesla injected parotid MRI performed as part of routine care for characterization, to which two specific high resolution sequences will be added. Evaluation of the exact position of the parotid tumor relative to the trunk of the facial nerve and its first branches, classification into two categories: on contact (≤ 5 mm) or at a distance (> 5 mm).
  2. nd visit: Surgical intervention of the parotid tumor. The surgeon will specify the same data as that collected by the radiologists after the MRI.
  3. rd visit: Post-operative consultation in the week following the intervention. The surgeon will look for the occurrence of post-operative facial paralysis.
02

Conditions studied

  • Parotid Tumor

Browse trials for

03

In context

Parotid Neoplasms

28 studies on the registry are indexed under Parotid Neoplasms; 8 are open to participants now.

Browse Parotid Neoplasms studies →

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patient candidate for first line surgery for a parotid tumor

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years old
  • Patient candidate for surgery for a parotid tumor
  • Parotid tumor located near the trunk of the facial nerve and or its first branches of division according to the clinical examination of the ENT surgeon and the imaging data
  • Affiliate or beneficiary of a social security scheme
  • Written consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Personal history of parotid homolateral surgery
  • Absolute or relative to MRI
  • Known to gadolinic contrast media
  • Pre or post operative period of a liver transplant
  • Patient benefiting from a legal protection measure
  • Pregnant or lactating woman
  • Patient who has already benefited from a preoperative MRI to characterize a complete, well conducted and interpretable parotid lesion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
88 participants (estimated)
Patient registry
No

Interventions

  • OtherMRI

    All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor: 1. New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection; 2. Gold standard: Intraoperative examination.

06

What researchers measure

Primary outcomes

  1. measurements by the radiologist on the high resolution 3Tesla MRI with specific sequences.

    measurements by the radiologist on the high resolution 3Tesla MRI with specific sequences.

    Time frame: day 0

  2. assessment by the surgeon during the excision surgery of the parotid lesion

    assessment by the surgeon during the excision surgery of the parotid lesion

    Time frame: day 0

07

Study locations

1 of 1 sites recruiting
  • Fondation A De Rothschild
    Paris, PARIS 75019, France
    Recruiting
    • a YAVCHITZ · Contactayavchitz@for.paris · 0148036454
    • adrien Collin · Principal investigator
    • jean-Baptiste Lecanu · Principal investigator
    • Elisabeth SAUVAGET · Principal investigator
    • Stéphane HANS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Jan 2027, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Nov 3, 2020
StartActual
Jan 13, 2021
Primary completionEst.
Jan 13, 2027
CompletionEst.
May 13, 2027
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04613349
Responsible party
Sponsor
First posted
Nov 3, 2020
Start date
Jan 13, 2021
Primary completion
Jan 13, 2027 (estimated)
Completion
May 13, 2027 (estimated)
Last update
Jan 5, 2026

Study contacts

Amelie YAVCHITZ
Contact
ayavchitz@for.paris
0148036454
Adrien COLLIN
Contact
acollin@for.paris
0148036401

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion